BOSTON (

TheStreet

) -- Here's an updated list of biotech and pharmaceutical companies with FDA drug approval decisions expected in 2013.

Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst -- FDA drug approval decisions and advisory panels.

Johnson & Johnson

(JNJ) - Get Report

Drug/indication:

Canagliflozin for diabetes.

FDA advisory panel:

Jan. 10

Approval decision date:

March 29

Theravance

(THRX)

Drug/indication:

Vibativ for hospital acquired pneumonia

Approval decision date:

Jan. 11

Santarus

(SNTS)

Drug/indication:

Uceris for ulcerative colitis

Approval decision date:

Jan. 16

NuPathe

(PATH)

Drug/indication:

Zelrix for migraine

Approval decision date:

Jan. 17, 2013

Impax Labs

(IPXL)

Drug/indication:

IPX066 for Parkinson's disease

Approval decision date:

Jan. 21

Hyperion Therapeutics

(HPTX)

Drug/indication:

Ravicti for urea cycle disorder

Approval decision date:

Jan. 23

Sanofi

(SNY) - Get Report

and

Isis Pharmaceuticals

(ISIS)

Drug/indication:

Kynamro for dyslipidemia/hypercholesterolemia

Approval decision date:

Jan. 29, 2013

Raptor Pharmaceutical

(RPTP)

Drug/indication:

RP103 for cystinosis

Approval decision date:

Jan. 30, 2013

Hemispherx Biopharma

(HEB)

Drug/indication:

Ampligen for chronic fatigue syndrome

Approval decision date:

Feb. 1, 2013

Celgene

(CELG) - Get Report

Drug/indication:

Pomalidomide for multiple myeloma

Approval decision date:

Feb. 8, 2013

Dynavax

(DVAX) - Get Report

Drug/indication:

Heplisav for hepatitis B prevention

Approval decision date:

Feb. 22, 2013

Roche

(RHHBY)

and

Immunogen

(IMGN) - Get Report

Drug/indication:

T-DM1 for breast cancer

Approval decision date

Feb. 26

Zogenix

(ZGNX) - Get Report

Drug/indication:

Zohydro for chronic pain

Approval decision date:

March 1, 2013

Depomed

(DEPO)

Drug/indication:

Serada for menopause

FDA advisory panel:

March 4

Approval decision date:

May 31

Bristol-Myers Squibb

(BMY) - Get Report

Drug/indication:

Eliquis for blood clot prevention

Approval decision date:

March 15

A.P. Pharma

(APPA)

Drug/indication:

APF530 for chemotherapy induced nausea

Approval decision date:

March 27

Biogen Idec

(BIIB) - Get Report

Drug/indication:

BG-12 for multiple sclerosis

Approval decision date:

March 28

MAP Pharma

( MAPP)

Drug/indication:

Levadex for migraine

Approval decision date:

April 15

Sucampo Pharmaceuticals

(SCMP)

Drug/indication:

Amitzia for opioid-induced constipation

Approval decision date:

April 26

Navidea Biopharmaceuticals

(NAVB) - Get Report

Drug/indication:

Lymphoseek, a radioactive tracing agent for lymph node mapping

Approval decision date:

April 30

GlaxoSmithKline

(GSK) - Get Report

Drug/indication:

Dabrefenib for melanoma

FDA advisory panel:

June 3

Delcath Systems

(DCTH)

Drug/indication:

ChemoSat for liver metastases due to ocular melanoma

Approval decision date:

June 14

AVEO Pharmaceuticals

(AVEO) - Get Report

Drug/indication:

Tivozanib for kidney cancer

Approval decision date:

July 28

Companies with drugs filed to FDA but no assigned approval decision dates:

Auxillium Pharmaceuticals

(AUXL)

: Xiaflex for Peyronie's disease

Bayer

and

Algeta

: Alpharadin for prostate cancer

Antares Pharma

(ATRS) - Get Report

: Otrexup for rheumatoid arthritis

GlaxoSmithKline: Dolutegravir for HIV

Sources: Company reports,

TheStreet

research,

BioMedTracker

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.